Drug Trial Radar · NCT03622021
A Study of AK111 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Feb 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Aug 14, 2018
Primary completion
Sep 9, 2019
Study completion Sep 9, 2019
Sponsor
- Lead sponsor
- Akesobio Australia Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, randomized, double-blind, placebo-controlled, single dose-escalation first-in human study to evaluate the safety, tolerability, PK, PD and immunogenicity of AK111 in healthy subjects following SC administration. The study will consist of cohorts of healthy subjects. Cohort 1, four unique subjects will be randomized to receive either active AK111 (N=3) or matching placebo (N=1). Cohorts 2, 3, 4 and 5, eight unique subjects will be randomized to receive either active AK111 (N=6) or matching placebo (N=2). Approximately 36 subjects will be treated in this study.
Conditions
- Psoriasis
Interventions
AK111 or PlaceboDrug
All the subjects in each cohort will be randomized in a 3:1 ratio to receive either AK111 or Placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent AE/SAEsTime frame: From baseline through 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Christchurch Clinical Studies Trust (CCST)
Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.